Alaunos Therapeutics
TCRT
124 hedge funds and large institutions have $241M invested in Alaunos Therapeutics in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 38 increasing their positions, 28 reducing their positions, and 23 closing their positions.
110% more capital invested
Capital invested by funds: $115M → $241M (+$126M)
36% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 28
14% more call options, than puts
Call options by funds: $5.96M | Put options by funds: $5.23M
0.03% less ownership
Funds ownership: 0.29% → 0.26% (-0.03%)
9% less funds holding
Funds holding: 137 → 124 (-13)
57% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 23
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.6M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$4.9M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.26M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 5 |
Rafferty Asset Management
New York
|
+$583K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TS
Third Security
Radford,
Virginia
|
-$8.16M |
| 2 |
Citigroup
New York
|
-$1.03M |
| 3 |
D.E. Shaw & Co
New York
|
-$991K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$865K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$824K |
TCRT Hedge Fund Activity: Q1 2019 in Review
124 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2019, worth a combined $241M — up 110% from $115M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of TCRT and 10 opened new positions — a net loss of 13 holders — while 28 trimmed existing stakes and 38 added.
The largest buyer was Vanguard Group, adding an estimated $12.6M. The largest seller was Third Security, exiting entirely with an estimated $8.16M sold.
- 124 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2019, down from 137 in Q4 2018.
- Funds reported $241M of Alaunos Therapeutics stock for Q1 2019, up 110% quarter-over-quarter.
- 10 funds opened new Alaunos Therapeutics positions in Q1 2019 and 23 closed out, a net change of -13 holders.
- The largest Alaunos Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $12.6M added.
- The largest Alaunos Therapeutics seller in Q1 2019 was Third Security, an estimated $8.16M sold.
Based on aggregated 13F filings for Q1 2019.